DrugPatentWatch Database Preview
OBREDON Drug Profile
Email this page to a colleague
When do Obredon patents expire, and what generic alternatives are available?
Obredon is a drug marketed by Sovereign Pharms and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in OBREDON is guaifenesin; hydrocodone bitartrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the guaifenesin; hydrocodone bitartrate profile page.
DrugPatentWatch® Generic Entry Outlook for Obredon
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 13, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for OBREDON
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in OBREDON? | OBREDON excipients list |
| DailyMed Link: | OBREDON at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for OBREDON
Generic Entry Date for OBREDON*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for OBREDON
| Drug Class | Opioid Agonist |
| Mechanism of Action | Opioid Agonists |
ATC Classes for OBREDON
US Patents and Regulatory Information for OBREDON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sovereign Pharms | OBREDON | guaifenesin; hydrocodone bitartrate | SOLUTION;ORAL | 205474-001 | Nov 14, 2014 | DISCN | Yes | No | Get Started Free | Get Started Free | Y | Y | Get Started Free | ||
| Sovereign Pharms | OBREDON | guaifenesin; hydrocodone bitartrate | SOLUTION;ORAL | 205474-001 | Nov 14, 2014 | DISCN | Yes | No | Get Started Free | Get Started Free | Y | Y | Get Started Free | ||
| Sovereign Pharms | OBREDON | guaifenesin; hydrocodone bitartrate | SOLUTION;ORAL | 205474-001 | Nov 14, 2014 | DISCN | Yes | No | Get Started Free | Get Started Free | Y | Y | Get Started Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
